The Protein Brewery is a Dutch food-ingredients biotech founded in 2020 as a spin-out from BioscienZ by molecular biologist and fermentation specialist Wim de Laat (30+ years in industrial fermentation, ex-DSM). Its flagship ingredient Fermotein® is a whole-food mycoprotein produced by biomass fermentation of the thermophilic fungus Rhizomucor pusillus — a low-pH, high-temperature strain that grows largely under non-sterile conditions, making the process substantially less capital-intensive than most alternative-protein platforms. The dried mycelium delivers 50% complete protein, 30% prebiotic fibre, essential micronutrients (magnesium, zinc, choline, B vitamins), and naturally concentrated spermidine, with an LCA footprint roughly 1% of the land, 5% of the water, and 3% of the emissions per kg protein vs beef. Fermotein® was granted a positive EFSA opinion in December 2025 with EU novel-food authorisation for Q3 2026, on top of existing regulatory clearance in the US (self-GRAS + FDA GRAS notification in progress) and Singapore (SFA, 2024). Under CEO Thijs Bosch (ex-Cosun, ex-Fonterra), the company operates a 600 MT/year commercial plant in Breda (scaling to 2,000+ MT by 2029 in partnership with industrial-engineering firm Vandoren) and has raised roughly $70M+ total capital across a €22M Series A (Nov 2021, led by Novo Growth), a €30M Series B (Sept 2025), and a €18M Series B extension in 2026 — with investors including Novo Holdings, Invest-NL, ABN AMRO Sustainable Impact Fund, Roquette, Unovis, Madeli, and the Brabant Development Agency (BOM).